These results indicate that suppressing NLRP3 inflammasome activation may reduce neuroinflammation and ameliorate the pathophysiological processes of AD, and may therefore be a novel therapeutic strategy for AD. The gene discussed is NLRP3; the disease is Alzheimer disease.